Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

Tom Treasure, Loic Lang-Lazdunski, David Waller, Judith M Bliss, Carol Tan, James Entwisle, Michael Snee, Mary O'Brien, Gill Thomas, Suresh Senan, Ken O'Byrne, Lucy S Kilburn, James Spicer, David Landau, John Edwards, Gill Coombes, Liz Darlison, Julian Peto, MARS trialists, D Landau, L Lang-Lazdunski, M O'Brien, M Hatton, R Rintoul, G Thomas, D Waller, J Entwisle, M Snee, K Papagiannopoulos, J Thompson, R Brown, A Morgan, S Morgan, P Beckett, K Waite, A Chetiyawardana, E Lim, M Dusmet, J Edwards, Tom Treasure, Loic Lang-Lazdunski, David Waller, Judith M Bliss, Carol Tan, James Entwisle, Michael Snee, Mary O'Brien, Gill Thomas, Suresh Senan, Ken O'Byrne, Lucy S Kilburn, James Spicer, David Landau, John Edwards, Gill Coombes, Liz Darlison, Julian Peto, MARS trialists, D Landau, L Lang-Lazdunski, M O'Brien, M Hatton, R Rintoul, G Thomas, D Waller, J Entwisle, M Snee, K Papagiannopoulos, J Thompson, R Brown, A Morgan, S Morgan, P Beckett, K Waite, A Chetiyawardana, E Lim, M Dusmet, J Edwards

Abstract

Background: The effects of extra-pleural pneumonectomy (EPP) on survival and quality of life in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed in a randomised trial. We aimed to assess the clinical outcomes of patients who were randomly assigned to EPP or no EPP in the context of trimodal therapy in the Mesothelioma and Radical Surgery (MARS) feasibility study.

Methods: MARS was a multicentre randomised controlled trial in 12 UK hospitals. Patients aged 18 years or older who had pathologically confirmed mesothelioma and were deemed fit enough to undergo trimodal therapy were included. In a prerandomisation registration phase, all patients underwent induction platinum-based chemotherapy followed by clinical review. After further consent, patients were randomly assigned (1:1) to EPP followed by postoperative hemithorax irradiation or to no EPP. Randomisation was done centrally with computer-generated permuted blocks stratified by surgical centre. The main endpoints were feasibility of randomly assigning 50 patients in 1 year (results detailed in another report), proportion randomised who received treatment, proportion eligible (registered) who proceeded to randomisation, perioperative mortality, and quality of life. Patients and investigators were not masked to treatment allocation. This is the principal report of the MARS study; all patients have been recruited. Analyses were by intention to treat. This trial is registered, number ISRCTN95583524.

Findings: Between Oct 1, 2005, and Nov 3, 2008, 112 patients were registered and 50 were subsequently randomly assigned: 24 to EPP and 26 to no EPP. The main reasons for not proceeding to randomisation were disease progression (33 patients), inoperability (five patients), and patient choice (19 patients). EPP was completed satisfactorily in 16 of 24 patients assigned to EPP; in five patients EPP was not started and in three patients it was abandoned. Two patients in the EPP group died within 30 days and a further patient died without leaving hospital. One patient in the no EPP group died perioperatively after receiving EPP off trial in a non-MARS centre. The hazard ratio [HR] for overall survival between the EPP and no EPP groups was 1·90 (95% CI 0·92-3·93; exact p=0·082), and after adjustment for sex, histological subtype, stage, and age at randomisation the HR was 2·75 (1·21-6·26; p=0·016). Median survival was 14·4 months (5·3-18·7) for the EPP group and 19·5 months (13·4 to time not yet reached) for the no EPP group. Of the 49 randomly assigned patients who consented to quality of life assessment (EPP n=23; no EPP n=26), 12 patients in the EPP group and 19 in the no EPP group completed the quality of life questionnaires. Although median quality of life scores were lower in the EPP group than the no EPP group, no significant differences between groups were reported in the quality of life analyses. There were ten serious adverse events reported in the EPP group and two in the no EPP group.

Interpretation: In view of the high morbidity associated with EPP in this trial and in other non-randomised studies a larger study is not feasible. These data, although limited, suggest that radical surgery in the form of EPP within trimodal therapy offers no benefit and possibly harms patients.

Funding: Cancer Research UK (CRUK/04/003), the June Hancock Mesothelioma Research Fund, and Guy's and St Thomas' NHS Foundation Trust.

Copyright © 2011 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial design BTS=British Thoracic Society. MARS=Mesothelioma and Radical Surgery. EPP=extra-pleural pneumonectomy.
Figure 2
Figure 2
Feasibility of registration and recruitment to MARS Numbers in brackets indicate those patients screened who did not have chemotherapy before registration. MARS=Mesothelioma and Radical Surgery. MDT=multidisciplinary team. EPP=extra-pleural pneumonectomy.
Figure 3
Figure 3
Feasibility of EPP surgery and radical radiotherapy treatment EPP=extra-pleural pneumonectomy. *Subsequent perioperative death. †Other complications were flexible bronchoscopy or drain infection in pneumonectomy cavity; ischaemic right leg requiring femoropopliteal bypass and eventual below knee amputation with culture-positive pneumonia needing mini tracheostomy. ‡Postoperative pain, low blood pressure, and intraoperative bleeding and further bleeding from chest drains postoperatively.
Figure 4
Figure 4
Overall survival EPP=extra-pleural pneumonectomy.
Figure 5
Figure 5
Recurrence-free and progression-free survival Recurrence-free survival in patients randomised to EPP (A) and progression-free survival in patients randomly assigned to no EPP (B). EPP=extra-pleural pneumonectomy.
Figure 6
Figure 6
Quality of life

References

    1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–539.
    1. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92:587–593.
    1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–672.
    1. Sugarbaker DJ, Flores RM, Jaklitsch MT. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.
    1. Rusch VW, Rosenzweig K, Venkatraman E. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;22:788–795.
    1. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002;22:298–305.
    1. Stewart DJ, Martin-Ucar A, Pilling JE, Edwards JG, O'Byrne KJ, Waller DA. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg. 2004;78:245–252.
    1. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183–1185.
    1. Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. BMJ. 2004;328:237–238.
    1. Tan C, Swift S, Gilham C. Survival in surgically diagnosed patients with malignant mesothelioma in current practice. Thorax. 2002;57(iii):36.
    1. Treasure T, Waller D, Tan C. The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol. 2009;4:1254–1258.
    1. British Thoracic Society. Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56:89–108.
    1. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122–1128.
    1. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692–1703.
    1. Weder W, Stahel RA, Bernhard J. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–1202.
    1. Rea F, Marulli G, Bortolotti L. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57:89–95.
    1. Krug LM, Pass HI, Rusch VW. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013.
    1. De Perrot M, Feld R, Cho BC. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–1418.
    1. Van Schil PE, Baas P, Gaafar R. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362–1369.
    1. Sugarbaker DJ, Jaklitsch MT, Bueno R. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–146.
    1. Opitz I, Kestenholz P, Lardinois D. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2006;29:579–584.
    1. Flores RM, Pass HI, Seshan VE. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–626.
    1. Rice DC, Stevens CW, Correa AM. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–1692.
    1. Tilleman TR, Richards WG, Zellos L. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–411.
    1. Flores RM, Zakowski M, Venkatraman E. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–965.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner